KR101832286B1 - Composition for improving skin wrinkle and enhancing elasticity - Google Patents
Composition for improving skin wrinkle and enhancing elasticity Download PDFInfo
- Publication number
- KR101832286B1 KR101832286B1 KR1020120039946A KR20120039946A KR101832286B1 KR 101832286 B1 KR101832286 B1 KR 101832286B1 KR 1020120039946 A KR1020120039946 A KR 1020120039946A KR 20120039946 A KR20120039946 A KR 20120039946A KR 101832286 B1 KR101832286 B1 KR 101832286B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- weight
- skin
- improving
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 230000037303 wrinkles Effects 0.000 title claims abstract description 41
- 230000002708 enhancing effect Effects 0.000 title 1
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 229920001436 collagen Polymers 0.000 claims abstract description 25
- 239000002537 cosmetic Substances 0.000 claims abstract description 21
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 15
- 230000037394 skin elasticity Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 81
- 239000004480 active ingredient Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 20
- -1 patch Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000006210 lotion Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000686 essence Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 10
- 210000002950 fibroblast Anatomy 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 12
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 12
- 229950008559 valtrate Drugs 0.000 description 12
- 239000003755 preservative agent Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000003205 fragrance Substances 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 239000000049 pigment Substances 0.000 description 10
- 229920002498 Beta-glucan Polymers 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 229940113124 polysorbate 60 Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical class OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 239000004475 Arginine Chemical class 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical class SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical class CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical class NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical class CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical class [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical class OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Chemical class 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical class CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 피부 주름 개선 및 탄력 증진용 조성물에 관한 것이다. 보다 상세하게는, 본 발명에 따른 발트레이트는 피부의 섬유아세포의 콜라겐 합성을 촉진하여 주름 개선 및 피부의 탄력을 향상시키는 효과를 나타냄으로써 의약품, 화장료 또는 식품 조성물로서 사용 가능하다.The present invention relates to a composition for improving skin wrinkles and improving elasticity. More specifically, the present invention can be used as medicines, cosmetics or food compositions by promoting collagen synthesis of fibroblasts of the skin to improve wrinkles and skin elasticity.
Description
본 발명은 피부 주름 개선 및 탄력 증진용 조성물에 관한 것이다.
The present invention relates to a composition for improving skin wrinkles and improving elasticity.
콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로서 세포외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포분할과 분화(유기체의 성장 혹은 상처 치유시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다. 또한, 근래에 들어 피부 노화에 대한 광범위한 연구가 발전하면서 피부에서의 콜라겐의 중요한 기능이 밝혀지고 있다.Collagen is a major substrate protein produced in fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical rigidity of skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, division of cells and differentiation Growth or wound healing) are known. Such collagen is reduced by aging and photo aging caused by ultraviolet irradiation, which is known to be closely related to the wrinkling of the skin. In addition, in recent years, extensive research on skin aging has developed and important functions of collagen in skin have been revealed.
종래에는 콜라겐의 피부 보습 효과로부터 화장품에 콜라겐을 배합하는 제품들이 출시되어 있으나, 이들 화장품은 콜라겐을 피부 표면에 도포하는 것으로, 고분자인 콜라겐의 경피 흡수에 의한 보습작용을 기대할 수 없으므로 본질적인 피부 기능 개선이라고 말할 수 없다.In the prior art, there have been products that incorporate collagen into cosmetics from the skin moisturizing effect of collagen, but these cosmetics apply collagen to the skin surface, and since the collagen, which is a polymer, can not be expected to be moisturized by transdermal absorption, Can not be said.
한편, 콜라겐 합성 촉진하여 주름 개선 효과를 나타내는 유효성분들이 알려져 있다. 예를 들어, 레티노산(retinoic acid), TGF(transforming growth factor)[비특허문헌 1], 동물 태반 유래의 단백질[특허문헌 1], 베튤린산(betulinic acid)[특허문헌 2], 클로렐라 추출물[특허문헌 3, 4] 등이 콜라겐 합성 촉진 물질로서 알려져 있다. 그러나, 상기 유효성분들은 피부 적용 시 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 피부의 콜라겐 합성을 촉진하여 피부 기능을 개선하는 효과를 기대할 수 없는 문제점이 있다. 따라서, 생체에 안전하고, 유효성분이 안정하며, 무엇보다도 기존의 콜라겐 합성 촉진 물질보다 효과가 우수한 주름 개선 활성을 지닌 성분의 개발이 절실히 요망되고 있다.
On the other hand, there are known effective substances that promote collagen synthesis and exhibit wrinkle-reducing effects. For example, retinoic acid, transforming growth factor (TGF) [non-patent document 1], animal placenta-derived protein [Patent document 1], betulinic acid [Patent document 2], chlorella extract [ Patent Documents 3 and 4] are known as collagen synthesis promoting substances. However, the above-mentioned effective ingredients are limited in the use amount due to safety problems such as irritation and redness when applied to the skin, or have insufficient effect, so that the effect of improving the skin function by promoting the collagen synthesis of the skin can not be expected. Therefore, there is a desperate need to develop a wrinkle-improving active ingredient that is safe for living body, stable in its effective component, and most effective than the existing collagen synthesis promoting substance.
이에, 본 발명자들은 발트레이트(valtrate)가 피부의 섬유아세포의 콜라겐 합성을 촉진함으로써, 피부의 탄력을 향상시키고 주름을 개선시키는 효과를 확인함으로써 본 발명을 완성하게 되었다.Accordingly, the present inventors have completed the present invention by confirming the effect that valtrate promotes collagen synthesis of fibroblasts of the skin, thereby improving skin elasticity and improving wrinkles.
따라서, 본 발명의 목적은 발트레이트를 유효성분으로 함유하는 피부 주름 개선 및 탄력 증진용 조성물을 제공하는데 있다.
Accordingly, an object of the present invention is to provide a composition for improving skin wrinkles and elasticity, which comprises a wortrate as an active ingredient.
상기 과제를 해결하기 위한 수단으로서, 본 발명은 하기 화학식 1로 표현되는 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 약학적 조성물을 제공한다:As a means for solving the above problems, the present invention provides a pharmaceutical composition for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1): < EMI ID =
[화학식 1][Chemical Formula 1]
상기 과제를 해결하기 위한 다른 수단으로서, 본 발명은 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 피부 외용제를 제공한다.
As another means for solving the above problems, the present invention provides a skin external preparation for skin wrinkle improvement and elasticity enhancement comprising the compound of formula (1).
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 화장료 조성물을 제공한다.
As another means for solving the above problems, the present invention provides a cosmetic composition for improving skin wrinkles and improving elasticity comprising the compound of formula (1).
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 건강식품을 제공한다.
As another means for solving the above problems, the present invention provides a health food for improving skin wrinkles and improving elasticity comprising the compound of formula (1).
본 발명에 따른 발트레이트(valtrate)는 피부의 섬유아세포의 콜라겐 합성을 촉진하여 피부의 탄력을 향상시키고 주름을 개선시키는 효과를 나타내며 세포독성이 없어 부작용 없이 의약품, 화장료 또는 건강식품에 사용할 수 있다.
The valtrate according to the present invention promotes the collagen synthesis of the fibroblasts of the skin to improve the elasticity of the skin and improve the wrinkles. The valtrate according to the present invention has no cytotoxicity and can be used for medicines, cosmetics or health foods without side effects.
이하, 본 발명의 구성을 구체적으로 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
피부 주름 개선 성분이 실제 피부에 적용 시 우수한 피부 주름 개선 효과를 발휘하기 위해서는 저농도에서 고활성의 주름 개선 활성을 나타내고, 피부를 투과하여 흡수되는 능력이 우수하고, 피부 주름 개선 효과를 나타내기에 충분한 시간 동안 머무를 수 있도록 휘발성이 낮고, 조성물이나 피부 상에서 활성 성분이 안정하게 유지되고, 의약이나 화장품으로의 제형화가 용이하며, 또한 피부에 안전한 것이 바람직하다. 그러나, 공지의 피부 주름 개선 성분 중 상기 특성을 모두 만족시키는 피부 주름 개선 성분은 흔치 않다. 예를 들어, 몇몇 주름 개선 성분들은 시험관 내 실험 시 저농도에서도 주름 개선 활성은 우수하나, 피부를 투과하여 흡수되는 능력이 떨어져 실제 피부에 적용하기엔 어렵다. 또 다른 피부 주름 개선 성분들은 친수성이 낮아 의약이나 화장품으로 제형화가 어렵다. 또한, 몇몇 피부 주름 개선 성분들은 열, 광, 또는 산소에 노출되었을 때 주름 개선 성분이 분해되거나 다른 화합물로 변형되어 피부에 적용하기 전에 이미 주름 개선 효과가 사라지는 경우도 있다.In order to exhibit an excellent skin wrinkle-reducing effect when the skin wrinkle improving ingredient is applied to actual skin, it exhibits a high active wrinkle reducing activity at a low concentration, exhibits excellent ability to penetrate and absorb the skin, And it is preferable that the active ingredient is kept stable on the composition or on the skin, is easy to be formulated into medicines or cosmetics, and is safe for the skin. However, among the known skin wrinkle improving ingredients, the wrinkle improving ingredients that satisfy all of the above characteristics are not common. For example, some wrinkle-improving ingredients have excellent wrinkle-reducing activity even at low concentrations in vitro, but they are difficult to apply to real skin because of their ability to permeate through the skin. Other skin wrinkle-reducing ingredients have low hydrophilicity and are difficult to formulate into medicines or cosmetics. In addition, some skin wrinkle remedies may degrade wrinkles when they are exposed to heat, light, or oxygen, or they may be transformed into other compounds to wrinkle-reducing effects before they are applied to the skin.
하기 실시예에서 확인할 수 있는 바와 같이, 발트레이트(valtrate)는 저농도에서 월등히 우수한 콜라겐 합성 촉진 효과를 나타내므로, 피부 주름 개선, 탄력 증진을 위한 의약품, 화장료, 건강식품 등의 유효성분으로 사용할 수 있다.As can be seen from the following examples, valtrate shows excellent collagen synthesis promoting effect at a low concentration, and thus can be used as an effective ingredient for improving the skin wrinkles, improving the elasticity, cosmetics, and health food .
따라서, 본 발명은 하기 화학식 1로 표현되는 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 약학적 조성물을 제공한다:Accordingly, the present invention provides a pharmaceutical composition for improving skin wrinkles and improving elasticity comprising a compound represented by the following Formula 1:
[화학식 1][Chemical Formula 1]
상기 화학식 1의 화합물의 화합물명은 Valtrate;VALTRATE(P);VALTRATE(P)(PLEASE CALL); (1S,7R)-4-Acetoxymethyl-6,7aα-dihydrospiro[cyclopenta[c]pyran-7(1H),2'-oxirane]-1α,6α-diol1,6-bis(3-methylbutanoate); 또는 [(1S,6S,7aS)-4-(Acetyloxymethyl)-1-(3-methylbutanoyloxy)spiro[6,7a-dihydro-1H-cyclopenta[c]pyran-7,2'-oxirane]-6-yl]3-methylbutanoate라 하며, 일명 발트레이트(valtrate)라 한다. The compound name of the compound of Formula 1 is Valtrate; VALTRATE (P); VALTRATE (P) (PLEASE CALL); (1S, 7R) -4-Acetoxymethyl-6,7aa-dihydrospiro [cyclopenta [c] pyran-7 (1H), 2'-oxirane] -1α, 6α-diol 1,6-bis (3-methylbutanoate); Or [(1S, 6S, 7aS) -4- (Acetyloxymethyl) -1- (3-methylbutanoyloxy) spiro [6,7a-dihydro-1H- cyclopenta [c] pyran-7,2'- ] 3-methylbutanoate, also known as valtrate.
상기 화학식 1의 화합물은 합성하여 이용하거나, 시판되고 있는 화합물을 이용할 수 있다. The compound of formula (1) may be synthesized or a commercially available compound may be used.
본 발명의 피부 주름 개선 및 탄력 증진용 약학적 조성물은 상기 화학식 1의 화합물의 약제학적으로 허용 가능한 염을 포함할 수 있다.The pharmaceutical composition for improving skin wrinkles and improving the elasticity of the present invention may comprise a pharmaceutically acceptable salt of the compound of formula (1).
상기 화학식 1의 화합물의 약제학적으로 허용 가능한 염은 유기산 또는 무기산을 이용하여 형성된 산 부가염일 수 있으며, 상기 유기산은, 예를 들면 포름산, 아세트산, 프로피온산, 락트산, 부티르산, 이소부티르산, 트리플루오로아세트산, 말산, 말레산, 말론산, 푸마르산, 숙신산, 숙신산 모노아미드, 글루탐산, 타르타르산, 옥살산, 시트르산, 글리콜산, 글루쿠론산, 아스코르브산, 벤조산, 프탈산, 살리실산, 안트라닐산, 디클로로아세트산, 아미노옥시 아세트산, 벤젠술폰산, p-톨루엔술폰산 및 메탄술폰산계 염을 포함하며 무기산은 예를 들면 염산, 브롬산, 황산, 인산, 질산, 탄산 및 붕산계 염을 포함한다. 바람직하게는 염산염 또는 아세트산염 형태일 수 있으며, 보다 바람직하게는 염산염 형태일 수 있다.The pharmaceutically acceptable salt of the compound of Formula 1 may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid The organic acid may be selected from the group consisting of hydrochloric acid, hydrobromic acid, hydrochloric acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, , Benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid-based salts, and the inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.
상기 언급된 산 부가염은 a) 상기 화학식 1의 화합물 및 산을 직접 혼합하거나, b) 이들 중 한 가지를 용매 또는 함수 용매 중에 용해시키고 혼합시키거나, 또는 c) 화학식 1의 화합물을 용매 또는 수하 용매 중의 산에 위치시키고 이들을 혼합하는 일반적인 염 제조방법으로 제조된다.The above-mentioned acid addition salts may be obtained by a) directly mixing the compound of formula 1 and an acid, or b) dissolving and mixing one of them in a solvent or a water solvent, or c) Lt; RTI ID = 0.0 > acid < / RTI > in a solvent and mixing them.
위와는 별도로 추가적으로 염이 가능한 형태는 가바염, 가바펜틴염, 프레가발린염, 니코틴산염, 아디페이트염, 헤미말론산염, 시스테인염, 아세틸시스테인염, 메티오닌염, 아르기닌염, 라이신염, 오르니틴염, 아스파르트산염 등이 있다. In addition to the above, additionally saltable forms include, but are not limited to, the salts of gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, Aspartate and the like.
본 발명의 약학적 조성물에 포함되는 상기 화학식 1의 화합물 또는 이의 약제학적으로 허용 가능한 염은 전체 약학적 조성물 대비 0.0001 내지 10 중량%로 포함될 수 있다. 보다 구체적으로 0.001 중량% 내지 1 중량%로 포함할 수 있다. 본 발명의 조성물이 상기 화학식 1의 화합물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 주름 개선, 탄력 증진 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.
The compound of Formula 1 or a pharmaceutically acceptable salt thereof contained in the pharmaceutical composition of the present invention may be contained in an amount of 0.0001 to 10% by weight based on the total pharmaceutical composition. More specifically 0.001% by weight to 1% by weight. When the composition of the present invention contains less than 0.0001% by weight of the compound of formula (I), sufficient wrinkle improvement and elasticity improvement effect can not be expected. When the composition contains more than 10% by weight, This is to prevent skin safety problems.
또한, 본 발명의 상기 화학식 1의 화합물을 의약품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 주름 개선 성분 또는 탄력 증진 성분을 포함할 수 있을 것이다. 추가적인 피부 주름 개선 성분, 탄력 증진 성분 미백 성분을 포함하게 되면 본 발명의 조성물의 주름 개선, 탄력 증진 효과는 더욱 증진될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 본 발명의 한 구체예에서, 상기 조성물은 당업계에 공지된 주름 개선 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베튤린산 및 클로렐라 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 피부 주름 개선 성분을 추가로 포함할 수 있다. 추가의 피부 주름 개선 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 콜라겐 합성 촉진 활성, 피부 안전성, 상기 화학식 1의 화합물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.
When the compound of Chemical Formula 1 of the present invention is used as a medicine, it may further contain one or more active ingredients showing the same or similar functions. For example, a known skin wrinkle-improving component or elasticity-enhancing component may be included. When the additional skin wrinkle-improving ingredient and the elasticity-enhancing ingredient whitening ingredient are included, the effect of improving the wrinkle and elasticity of the composition of the present invention may be further enhanced. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. In one embodiment of the present invention, the composition is a wrinkle-improving ingredient known in the art and includes one or more than one selected from the group consisting of retinoic acid, TGF, protein from animal placenta, betulinic acid and chlorella extract And may further comprise a skin wrinkle improving ingredient. The additional skin wrinkle improving ingredient may be contained in an amount of 0.0001 wt% to 10 wt% with respect to the weight of the whole composition, and the content range may be selected from the group consisting of collagen synthesis promoting activity, skin safety, ease of formulation of the compound of Formula 1 May be adjusted according to the requirements.
또한, 본 발명의 피부 주름 개선 및 탄력 증진용 약학적 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다. In addition, the pharmaceutical composition for improving skin wrinkles and improving elasticity of the present invention may further comprise a pharmaceutically acceptable carrier.
약학적으로 허용되는 담체는 완충액, 주사용 멸균수, 일반 식염수 또는 인산염 완충 식염수, 수크로스, 히스티딘, 염 및 폴리솔베이트 등과 같은 여러 성분을 함유할 수 있다.Pharmaceutically acceptable carriers may contain a variety of ingredients such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbates, and the like.
본 발명의 약학적 조성물은 경구 또는 비경구로 투여할 수 있으며, 일반 의약품 제제의 형태, 예를 들어, 임상 투여 시 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. The pharmaceutical composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, various forms of oral and parenteral administration at the time of clinical administration. In the case of formulation, , An extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 약학적 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(Calcium carbonate), 수크로스(Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제될 수 있다.Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 명세서에서, '주름 개선'이라 함은 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. As used herein, the term " wrinkle reduction " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating wrinkles that have already been generated.
본 발명의 약학적 조성물은 유효량의 상기 화학식 1의 화합물을 포함할 때 바람직한 주름 개선 효과, 탄력 증진 효과를 제공할 수 있다. 본 발명에 있어서, '유효량'이라 함은 피부의 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시킬 수 있는 화합물의 양을 의미한다. 본 발명의 조성물에 포함되는 상기 화학식 1의 화합물의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 것이다. 예컨대, 상기 조성물이 피부의 주름 생성, 탄력 감소, 기미 등에 따른 피부과적 치료를 위한 의약품으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 상기 화학식 1의 화합물을 포함할 수 있을 것이다. 따라서, 일일 투여량은 상기 화학식 1의 화합물의 양을 기준으로 0.1 내지 100 ㎎/㎏이고, 바람직하게는 30 내지 80 ㎎/㎏이고, 더욱 바람직하게는 50 내지 60 mg/kg이며, 하루 1 ∼ 6 회 투여될 수 있다. The pharmaceutical composition of the present invention can provide a desirable wrinkle-improving effect and elasticity-enhancing effect when an effective amount of the compound of Formula 1 is included. In the present invention, the term "effective amount" refers to the amount of a compound capable of inhibiting or inhibiting the generation of wrinkles of the skin or alleviating the wrinkles already formed. An effective amount of the compound of formula (1) contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, how the compound is applied to the skin, and the time on the skin. For example, when the composition is commercialized as a medicament for dermatological treatment due to wrinkle formation, elasticity reduction, and stain on the skin, the compound of formula 1 may be added at a higher concentration than the case where it is commercialized as a cosmetic product applied to the skin. . Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of the compound of formula (1) 6 times a day.
본 발명의 약학적 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.
The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
본 발명은 또한 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 피부 외용제를 제공한다.The present invention also provides a skin external preparation for skin wrinkle improvement and elasticity enhancement comprising the compound of formula (1).
상기 화학식 1의 화합물을 피부외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. When the compound of formula (1) is used as an external preparation for skin, it may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, , Water, ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for skin And any other ingredients used in the skin sciences. The components can also be introduced in amounts commonly used in the field of dermatology.
상기 화학식 1의 화합물이 피부 외용제 제형으로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제와 같은 제형을 가질 수 있다.When the compound of Formula 1 is provided as an external preparation for skin, it may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.
본 발명의 피부 주름 개선 및 탄력 증진용 피부 외용제에 포함되는 상기 화학식 1의 화합물은 전체 피부 외용제 대비 0.0001 내지 10 중량%로 포함될 수 있다. 보다 구체적으로 0.001 중량% 내지 1 중량%로 포함할 수 있다. 본 발명의 피부 외용제가 상기 화학식 1의 화합물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 주름 개선, 탄력 증진 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.
The compound of Formula 1 contained in the external preparation for skin wrinkle improvement and elasticity enhancement of the present invention may be contained in an amount of 0.0001 to 10% by weight relative to the total external preparation for skin. More specifically 0.001% by weight to 1% by weight. When the external preparation for skin of the present invention contains less than 0.0001% by weight of the compound of the formula 1, sufficient wrinkle improvement and elasticity enhancement effects can not be expected. When it exceeds 10% by weight, Or to prevent skin safety problems.
본 발명은 또한 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 화장료 조성물을 제공한다.The present invention also provides a cosmetic composition for improving skin wrinkles and improving elasticity comprising the compound of formula (1).
상기 화학식 1의 화합물을 화장품으로 사용하는 경우, 상기 화학식 1의 화합물을 유효성분으로 함유하여 제조되는 화장품은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. When the compound of Chemical Formula 1 is used as a cosmetic, the cosmetic product containing the compound of Chemical Formula 1 as an active ingredient may be prepared in the form of a general emulsified formulation and a solubilized formulation. For example, creams, essences, cosmetic creams, sprays, gels, packs, sunscreens, make-up bases, liquids such as lotions such as lotion, facial lotion, body lotion, A powder, a cleansing lotion, a makeup removing agent such as a cleansing oil, a cleaning agent such as a cleansing foam, a soap, a body wash and the like.
또한, 상기 화장료 조성물은 상기 화학식 1의 화합물에 추가로 화장료 조성물에 통상적으로 사용되는 안정화제, 용해화제, 비타민, 안료 또는 향료 등의 보조제 및 담체를 추가로 포함할 수 있다. 예컨대, 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetic composition may further include auxiliary agents and carriers such as stabilizers, solubilizers, vitamins, pigments or fragrances commonly used in cosmetic compositions, in addition to the compounds of formula (1). For example, it is also possible to use other additives such as fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, In the cosmetology field, such as metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in cosmetics And may contain auxiliary agents used.
상기 화학식 1의 화합물은 화장품으로 제품화되는 경우에 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워쉬-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 화학식 1의 화합물을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워쉬-오프 타입의 화장품에 비해 낮은 농도의 상기 화학식 1의 화합물을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 상기 화학식 1의 화합물을 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%, 보다 구체적으로 0.001 중량% 내지 1 중량%로 포함할 수 있다. 본 발명의 조성물이 상기 화학식 1의 화합물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 주름 개선, 탄력 증진 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다. In the case of a wash-off type cosmetic such as a make-up removing agent, a detergent, etc. in which the active ingredient remains on the skin in a short period of time when the compound of formula (1) is produced into a cosmetic product, . On the other hand, in the case of leave-on type cosmetics, such as lotion, cream, essence, etc., in which the active ingredient remains on the skin for a long period of time, It may be included. In one embodiment of the present invention, but not limited thereto, the composition may comprise from 0.0001% to 10%, more specifically from 0.001% to 1% by weight of the compound of Formula 1, have. When the composition of the present invention contains less than 0.0001% by weight of the compound of formula (I), sufficient wrinkle improvement and elasticity improvement effect can not be expected. When the composition contains more than 10% by weight, This is to prevent skin safety problems.
본 발명은 또한 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 탄력 증진용 건강식품에 관한 것이다.The present invention also relates to a health food for improving skin wrinkles and improving elasticity comprising the compound of formula (1).
본 명세서에서 '건강식품'이란, 상기 화학식 1의 화합물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과가 있는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있다.The term 'health food' as used herein means a food prepared by adding the compound of formula (1) to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering or suspension, However, unlike general medicine, there is an advantage that there is no side effect that may occur when a drug is taken for a long time by using a food as a raw material.
이와 같이 하여 얻어지는 본 발명의 건강식품은, 일상적으로 섭취하는 것이 가능하기 때문에 높은 피부 주름 개선 및 탄력 증진 효과를 기대할 수 있어 매우 유용하다.Since the health food of the present invention thus obtained can be ingested on a daily basis, it can be expected to have a high skin wrinkle improvement and an elasticity increasing effect, which is very useful.
상기 화학식 1의 화합물을 식품첨가물로 사용하는 경우, 상기 화학식 1의 화합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시 본 발명의 조성물은 원료에 대하여 15 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 더 구체적으로 0.0001 내지 10 중량%로 첨가된다. 보다 구체적으로, 0.001 내지 1 중량%로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. When the compound of Chemical Formula 1 is used as a food additive, the compound of Chemical Formula 1 may be added as it is or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). In general, the composition of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material. More specifically from 0.0001 to 10% by weight. More specifically, it is added in an amount of 0.001 to 1% by weight. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
본 발명의 건강음료는 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토오스, 수크로스와 같은 이당류; 덱스트린, 사이클로덱스트린과 같은 다당류; 또는 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강음료 100 mL 당 일반적으로 약 0.01 ∼ 0.04 g, 바람직하게는 약 0.02 ∼ 0.03 g 이다.The health drink of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Or sugar alcohols such as xylitol, sorbitol, and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the health drink of the present invention.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like.
그 밖에 본 발명의 건강식품은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 건강식품 100 중량부당 0.01 ∼ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.
In addition, the health food of the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<참조예 1> 화학식 1의 화합물의 정보≪ Reference Example 1 >
[화학식 1][Chemical Formula 1]
화합물명: Valtrate;VALTRATE(P);VALTRATE(P)(PLEASE CALL); (1S,7R)-4-Acetoxymethyl-6,7aα-dihydrospiro[cyclopenta[c]pyran-7(1H),2'-oxirane]-1α,6α-diol1,6-bis(3-methylbutanoate); 또는 [(1S,6S,7aS)-4-(Acetyloxymethyl)-1-(3-methylbutanoyloxy)spiro[6,7a-dihydro-1H-cyclopenta[c]pyran-7,2'-oxirane]-6-yl]3-methylbutanoateCompound name: Valtrate; VALTRATE (P); VALTRATE (P) (PLEASE CALL); (1S, 7R) -4-Acetoxymethyl-6,7aa-dihydrospiro [cyclopenta [c] pyran-7 (1H), 2'-oxirane] -1α, 6α-diol 1,6-bis (3-methylbutanoate); Or [(1S, 6S, 7aS) -4- (Acetyloxymethyl) -1- (3-methylbutanoyloxy) spiro [6,7a-dihydro-1H- cyclopenta [c] pyran-7,2'- ] 3-methylbutanoate
CAS No. : 18296-44-1CAS No. : 18296-44-1
기원 식물 : Valeriana officinalis var Origin: Valeriana officinalis there
일반명: 발트레이트(valtrate)
Common name: valtrate
<실시예 1> 콜라겐 합성능 확인Example 1 Confirmation of collagen aggregation performance
상기 화학식 1의 화합물을 인간 유래 섬유아세포의 배양액에 첨가하여 세포수준에서 콜라겐 합성 촉진 효과를 실험하였다. The compound of formula 1 was added to the culture medium of human-derived fibroblasts to examine the promoting effect of collagen synthesis at the cellular level.
합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT)를 이용하여 정량하였다. The synthesized collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immunoassay Kit).
실험 전 인간 유래 섬유아세포를 대상으로 실험물질의 농도 10 ppm, 1 ppm, 0.1 ppm, 0.01 ppm 및 0.001 ppm에서 MTT 시험을 통해 세포독성을 평가하였다. MTT 시험은 Mossman T.(1983), Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays, Journal of Immunological Methods vol.65, pp.55-63에 개시된 방법을 사용하였다. The cytotoxicity of human fibroblasts before the experiment was evaluated by MTT test at concentrations of 10 ppm, 1 ppm, 0.1 ppm, 0.01 ppm and 0.001 ppm of the test substance. The MTT assay was developed by Mossman T. (1983), Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays, Journal of Immunological Methods vol. 65, pp. 55-63.
상기 세포독성 결과 세포독성이 없는 농도를 선정하여 콜라겐 합성능을 평가하였다.The cytotoxicity results were evaluated by selecting the concentration without cytotoxicity.
실험에서 화학식 1의 화합물의 최종 농도는 0.01 ppm 및 0.001 ppm으로 하였으며, 각각의 시료는 인간 섬유아세포의 배양배지에 첨가하여 1일간 배양한 후, 배양액을 취하여 PICP EIA 키트로 각 농도에서의 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다. 효과의 비교를 위하여 아무것도 첨가하지 않은 섬유아세포의 배양 배지(대조군)와 비타민 C를 최종 농도 52.8 ㎍/mL가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성량은 UV 흡광도로서 측정하였으며, 콜라겐 생성 증가율은 대조군에 대한 상대적인 콜라겐 생성량 비율로 계산하고, 그 결과를 하기 표 1에 나타내었다.In the experiment, the final concentrations of the compound of Chemical Formula 1 were set to 0.01 ppm and 0.001 ppm, and each sample was added to the culture medium of human fibroblast for 1 day. Then, the culture broth was taken and the collagen synthesis Was measured at 450 nm using a spectrophotometer. For the comparison of the effects, the degree of collagen synthesis was measured by the same method for the culture medium of fibroblasts to which nothing was added (control group) and the sample added with vitamin C to a final concentration of 52.8 / / mL. The amount of collagen production was measured as the UV absorbance, and the increase rate of collagen production was calculated as a ratio of collagen production relative to the control. The results are shown in Table 1 below.
0.001 ppmBalt rate
0.001 ppm
0.01 ppmBalt rate
0.01 ppm
(52.8 ㎍/mL)Vitamin C
(52.8 [mu] g / mL)
상기 표 1의 결과에서 볼 수 있듯이, 발트레이트는 일반적으로 콜라겐 합성 능력이 있는 것으로 알려진 비타민 C를 적용한 경우 보다 적은 농도로 더 우수한 콜라겐 합성 효과를 발휘하였다.
As can be seen from the results in Table 1, the valtate exhibited better collagen synthesis effect at a lower concentration than that of vitamin C, which is generally known to have collagen synthesis ability.
<제제예 1> 약학적 제제의 제조≪ Formulation Example 1 > Preparation of pharmaceutical preparation
1. 산제의 제조1. Manufacturing of powder
화학식 1의 화합물 0.001g0.001 g of the compound of formula (1)
유당 1gLactose 1g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
2. 정제의 제조2. Preparation of tablets
화학식 1의 화합물 0.2㎎0.2 mg of the compound of formula (1)
옥수수전분 100㎎100 mg of corn starch
유 당 100㎎100 mg of milk
스테아린산Stearic acid 마그네슘 2㎎ Magnesium 2 mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
3. 캡슐제의 제조3. Preparation of capsules
화학식 1의 화합물 0.2㎎0.2 mg of the compound of formula (1)
옥수수전분 100㎎100 mg of corn starch
유 당 100㎎100 mg of milk
스테아린산Stearic acid 마그네슘 2㎎ Magnesium 2 mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
4. 환의 제조4. Manufacture of rings
화학식 1의 화합물 0.003g0.003 g of the compound of formula (1)
유당 1.5gLactose 1.5g
글리세린 1gGlycerin 1 g
자일리톨Xylitol 0.5g 0.5 g
상기의 성분을 혼합한 후, 통상의 방법에 따라 1 환 당 4 g이 되도록 제조하였다.
After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.
5. 과립의 제조5. Manufacture of granules
화학식 1의 화합물 2㎎2 mg of the compound of formula (1)
대두 추출물 50㎎Soybean extract 50 mg
포도당 200㎎200 mg of glucose
전분 600㎎600 mg of starch
상기의 성분을 혼합한 후, 30% 에탄올 100 ㎎을 첨가하여 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다.
After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 캜 to form granules, which were then filled in a capsule.
<제제예 2> 화장품의 제조≪ Formulation Example 2 > Preparation of cosmetics
1. 유연화장수(스킨로션)의 제조1. Manufacture of softening longevity (skin lotion)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 유연화장수를 통상의 방법에 따라 제조하였다.As the following composition, the number of softening times containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 1.0 중량％Beta-1,3-glucan 1.0 wt%
부틸렌글리콜 2.0 중량％Butylene glycol 2.0 wt%
프로필렌글리콜 2.0 중량％Propylene glycol 2.0 wt%
카르복시비닐폴리머 0.1 중량％Carboxyvinyl polymer 0.1 wt%
피이지-12 노닐페닐에테르 0.2 중량％0.2% by weight of phage-12 nonylphenyl ether
폴리솔베이트80 0.4 중량％Polysorbate 80 0.4 wt%
에탄올 10.0 중량％Ethanol 10.0 wt%
트리에탄올아민 0.1 중량％0.1% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수Purified water
toto
100 중량％ 100 wt%
2. 영양화장수(밀크로션)의 제조2. Manufacture of nutrition lotion (milk lotion)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 영양화장수를 통상의 방법에 따라 제조하였다.As in the following composition, a nutritional lotion containing the compound of the formula (1) as an active ingredient was prepared by a conventional method.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 1.0 중량％Beta-1,3-glucan 1.0 wt%
밀납 4.0 중량％4.0 wt%
폴리솔베이트60 1.5 중량％Polysorbate 60 1.5 wt%
솔비탄세스퀴올레이트 1.5 중량％1.5% by weight of sorbitan sesquioleate
유동파라핀 0.5 중량％0.5% by weight liquid paraffin
카프릴릭/카프릭트리글리세라이드 5.0 중량％Caprylic / capric triglyceride 5.0 wt%
글리세린 3.0 중량％Glycerin 3.0 wt%
부틸렌글리콜 3.0 중량％3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량％3.0% by weight of propylene glycol
카르복시비닐폴리머 0.1 중량％Carboxyvinyl polymer 0.1 wt%
트리에탄올아민 0.2 중량％0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수Purified water
toto
100 중량％ 100 wt%
3. 영양크림의 제조3. Manufacture of nutritional cream
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 영양크림을 통상의 방법에 따라 제조하였다.A nutritional cream containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.2 중량％0.2% by weight of the compound of formula (1)
베타-1,3-글루칸 5.0 중량％Beta-1,3-glucan 5.0 wt%
밀납 10.0 중량％Wax 10.0 wt%
폴리솔베이트60 1.5 중량％Polysorbate 60 1.5 wt%
피이지 60 경화피마자유 2.0 중량％≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량％0.5% by weight of sorbitan sesquioleate
유동파라핀 10.0 중량％Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량％Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량％Caprylic / capric triglyceride 5.0 wt%
글리세린 5.0 중량％Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량％3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량％3.0% by weight of propylene glycol
트리에탄올아민 0.2 중량％0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수Purified water
toto
100 중량％ 100 wt%
4. 마사지크림의 제조4. Manufacture of massage cream
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 마사지크림을 통상의 방법에 따라 제조하였다.A massage cream containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 3.0 중량％Beta-1,3-glucan 3.0 wt%
밀납 10.0 중량％Wax 10.0 wt%
폴리솔베이트60 1.5 중량％Polysorbate 60 1.5 wt%
피이지 60 경화피마자유 2.0 중량％≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.8 중량％0.8% by weight of sorbitan sesquioleate
유동파라핀 40.0 중량％Liquid paraffin 40.0 wt%
스쿠알란 5.0 중량％Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 4.0 중량％Caprylic / capric triglyceride 4.0 wt%
글리세린 5.0 중량％Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량％3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량％3.0% by weight of propylene glycol
트리에탄올아민 0.2 중량％0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수Purified water
toto
100 중량％ 100 wt%
5. 팩의 제조5. Manufacture of pack
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 팩을 통상의 방법에 따라 제조하였다.A pack containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.2 중량％0.2% by weight of the compound of formula (1)
베타-1,3-글루칸 1.0 중량％Beta-1,3-glucan 1.0 wt%
폴리비닐알콜 13.0 중량％Polyvinyl alcohol 13.0 wt%
소듐카르복시메틸셀룰로오스 0.2 중량％0.2% by weight of sodium carboxymethylcellulose,
글리세린 5.0 중량％Glycerin 5.0 wt%
알란토인 0.1 중량％Allantoin 0.1 wt%
에탄올 6.0 중량％6.0% by weight of ethanol
피이지 -12 노닐페닐에테르 0.3 중량％0.3% by weight of phage-12 nonylphenyl ether
폴리솔베이트 60 0.3 중량％Polysorbate 60 0.3 wt%
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수Purified water
toto
100 중량％ 100 wt%
6. 젤의 제조6. Manufacture of gel
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 젤을 통상의 방법에 따라 제조하였다.As in the following composition, a gel containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 0.1 중량％0.1% by weight of beta-1,3-glucan
에틸렌디아민초산나트륨 0.05 중량％0.05% by weight of sodium ethylenediaminetetraacetate
글리세린 5.0 중량％Glycerin 5.0 wt%
카르복시비닐폴리머 0.3 중량％Carboxyvinyl polymer 0.3 wt%
에탄올 5.0 중량％5.0% by weight of ethanol
피이지-60 경화피마자유 0.5 중량％≪ tb > < tb > < tb >
트리에탄올아민 0.3 중량％Triethanolamine 0.3 wt%
방부제 0.05 중량％ Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수Purified water
toto
100 중량％ 100 wt%
7. 연고의 제조7. Manufacture of ointment
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 연고를 통상의 방법에 따라 제조하였다.An ointment containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.5 중량％0.5% by weight of the compound of formula (1)
베타-1,3-글루칸 10.0 중량%Beta-1,3-glucan 10.0 wt%
밀납 10.0 중량%Wax 10.0 wt%
폴리솔베이트60 5.0 중량%Polysorbate 60 5.0 wt%
피이지 60 경화피마자유 2.0 중량%≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량%0.5% by weight of sorbitan sesquioleate
바셀린 5.0 중량%Vaseline 5.0 wt%
유동파라핀 10.0 중량%Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량%Squalane 5.0 wt%
쉐어버터 3.0 중량%SHARE BUTTER 3.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / capric triglyceride 5.0 wt%
글리세린 10.0 중량%Glycerin 10.0 wt%
프로필렌글리콜 10.2 중량%Propylene glycol 10.2 wt%
트리에탄올아민 0.2 중량%0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수Purified water
toto
100 중량% 100 wt%
8. 국소투여용 약제(겔 연고제) 의 제조8. Preparation of topical medicament (gel ointment)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 겔 연고제를 통상의 방법에 따라 제조하였다.A gel ointment agent containing the compound of the formula (1) as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.5 중량％0.5% by weight of the compound of formula (1)
베타-1,3-글루칸 10.0 중량%Beta-1,3-glucan 10.0 wt%
폴리아크릴산(Carbopol 940) 1.5 중량%1.5% by weight of polyacrylic acid (Carbopol 940)
이소프로판올 5.0 중량%5.0% by weight of isopropanol
헥실렌글리콜 25.0 중량%Hexylene glycol 25.0 wt%
트리에탄올아민 1.7 중량%Triethanolamine 1.7 wt%
탈이온수Deionized water
toto
100 중량% 100 wt%
9. 국소 투여용 약제(패취제)의 제조9. Preparation of topical medicines (patches)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 패취제를 통상의 방법에 따라 제조하였다.As the following composition, a patch containing a compound of the formula (1) as an active ingredient was prepared by a conventional method.
화학식 1의 화합물 0.5 중량%0.5% by weight of the compound of formula (1)
베타-1,3-글루칸 3.0 중량%Beta-1,3-glucan 3.0 wt%
헥실렌글리콜 20.0 중량%Hexylene glycol 20.0 wt%
디에틸아민 0.7 중량%Diethylamine 0.7 wt%
폴리아크릴산(Carbopol 934P) 1.0 중량%1.0% by weight of polyacrylic acid (Carbopol 934P)
아황산나트륨 0.1 중량%0.1% by weight of sodium sulfite
폴리옥시에틸렌라우릴에테르(E.O=9) 1.0 중량%1.0% by weight of polyoxyethylene lauryl ether (E.O. = 9)
폴리히드록시에틸렌세틸스테아릴에테르(Cetomacrogol 1000) 1.0 중량%1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000)
점성의 파라핀 오일 2.5 중량%Viscous paraffin oil 2.5 wt%
카프릴산에스테르/카프르산에스테르(Cetiol LC) 2.5 중량%2.5% by weight of caprylic acid ester / capric acid ester (Cetiol LC)
폴리에틸렌글리콜400 3.0 중량%Polyethylene glycol 400 3.0 wt%
탈이온수Deionized water
toto
100 중량% 100 wt%
<제제예 3> 식품의 제조≪ Formulation Example 3 > Preparation of food
본 발명의 화학식 1의 화합물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the compound of formula (I) of the present invention were prepared as follows.
1. 밀가루 식품의 제조1. Manufacture of Flour Food
상기 화학식 1의 화합물 0.05 ∼ 1.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강식품을 제조하였다.
0.05 to 1.0 part by weight of the compound of Formula 1 was added to wheat flour, and a bread, a cake, a cookie, a cracker and a noodle were prepared using the mixture to prepare a health food.
2. 유제품(dairy products)의 제조2. Manufacture of dairy products
상기 화학식 1의 화합물 0.2 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
0.2 part by weight of the compound of Formula 1 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
3. 선식의 제조3. Manufacturing of wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 상기 화학식 1의 화합물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a known method, and then they were prepared into powders having a particle size of 60 mesh by a grinder. The compound of Formula 1 was concentrated under reduced pressure in a vacuum concentrator, sprayed, and dried with a hot-air drier, and the resulting dried product was pulverized to a size of 60 mesh with a pulverizer to obtain a dried powder.
상기에서 제조한 곡물류, 종실류 및 화학식 1의 화합물의 건조분말을 혼합 분말 100 중량부에 대하여 다음의 비율로 배합하여 제조하였다.The grains, seeds, and dry powder of the compound of formula (1) prepared above were blended in the following proportions relative to 100 parts by weight of the mixed powder.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
화학식 1의 화합물(0.1 중량부),(1) (0.1 part by weight),
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 Rhubarb (0.5
중량부Weight portion
))
<제제예 4> 음료의 제조≪ Formulation Example 4 > Preparation of beverage
1. 건강음료의 제조1. Manufacture of health drinks
화학식 1의 화합물 0.1㎎0.1 mg of the compound of formula (1)
구연산 1000㎎Citric acid 1000 mg
올리고당 100gOligosaccharide 100 g
매실농축액 2gPlum concentrate 2g
타우린 1gTaurine 1g
정제수를Purified water 가하여 전체 900 All 900 mLmL
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2L-용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용하였다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring. Then, the solution thus prepared was filtered and sterilized in a sterilized 2L-container, Lt; RTI ID = 0.0 > health < / RTI >
상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
2. 야채주스의 제조2. Manufacture of vegetable juice
본 발명의 화학식 1의 화합물 1g을 토마토 또는 당근 주스 1,000mL에 가하여 건강 증진용 야채주스를 제조하였다.
1 g of the compound of formula (I) of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice for health promotion.
3. 과일주스의 제조3. Manufacture of fruit juice
화학식 1의 화합물 1 g을 사과 또는 포도 주스 1,000 mL에 가하여 건강 증진용 과일주스를 제조하였다.
1 g of the compound of formula (1) was added to 1,000 mL of apple or grape juice to prepare fruit juice for health promotion.
Claims (11)
[화학식 1]
A pharmaceutical composition for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
콜라겐 합성을 촉진하여 피부 주름을 개선하고 피부 탄력을 증진하는 것인 약학적 조성물.
The method according to claim 1,
To promote collagen synthesis to improve skin wrinkles and skin elasticity.
화학식 1의 화합물은 전체 조성물 대비 0.0001 내지 10 중량%로 포함되는 약학적 조성물.
The method according to claim 1,
Wherein the compound of formula (I) is contained in an amount of 0.0001 to 10% by weight based on the total composition.
[화학식 1]
An external skin preparation for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
상기 외용제는 연고, 패취, 겔, 크림 또는 분무제의 제형인 피부 외용제.
5. The method of claim 4,
Wherein the external preparation is a formulation of ointment, patch, gel, cream or spray.
화학식 1의 화합물은 전체 피부 외용제 대비 0.0001 내지 10 중량%로 포함되는 피부 외용제.
5. The method of claim 4,
Wherein the compound of formula (I) is contained in an amount of 0.0001 to 10% by weight relative to the total external preparation for skin.
[화학식 1]
A cosmetic composition for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션 또는 세정제의 제형인 화장료 조성물.
8. The method of claim 7,
Cosmetics, essences, lotions, creams, packs, gels, powders, foundations or detergents.
화학식 1의 화합물은 전체 조성물 대비 0.0001 내지 10 중량%로 포함되는 화장료 조성물.
8. The method of claim 7,
Wherein the compound of Formula 1 is contained in an amount of 0.0001 to 10% by weight relative to the total composition.
[화학식 1]
A health food for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
화학식 1의 화합물은 전체 건강식품 대비 0.0001 내지 10 중량%로 포함되는 건강식품.
11. The method of claim 10,
Wherein the compound of formula (1) is contained in an amount of 0.0001 to 10% by weight relative to the total health food.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120004449 | 2012-01-13 | ||
| KR1020120004449 | 2012-01-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130083774A KR20130083774A (en) | 2013-07-23 |
| KR101832286B1 true KR101832286B1 (en) | 2018-02-26 |
Family
ID=48994700
Family Applications (38)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120039942A KR101832285B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039950A KR20130083778A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039943A KR101890322B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039945A KR101792031B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039944A KR20130083772A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039946A KR101832286B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039941A KR101832284B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039949A KR101637375B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039948A KR101809753B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039947A KR101792028B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039940A KR101832283B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039951A KR101872916B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041768A KR101909235B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041759A KR101872918B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041767A KR101841256B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041770A KR101792029B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041756A KR101841255B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041761A KR101815000B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041757A KR101855094B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041758A KR101872917B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041769A KR101851625B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041760A KR101850711B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041766A KR101809754B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041765A KR101814999B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047636A KR101909236B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047637A KR20130083795A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047635A KR20130083793A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047640A KR101904916B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120047642A KR101839484B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120047638A KR101904917B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120047639A KR101853902B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047641A KR101931977B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120048923A KR101931978B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
| KR1020120048924A KR101855095B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
| KR1020120048928A KR101847013B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
| KR1020120048926A KR20130083804A (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
| KR1020120048927A KR101909237B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
| KR1020120048925A KR101847012B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120039942A KR101832285B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039950A KR20130083778A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039943A KR101890322B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039945A KR101792031B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039944A KR20130083772A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
Family Applications After (32)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120039941A KR101832284B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039949A KR101637375B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039948A KR101809753B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039947A KR101792028B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039940A KR101832283B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120039951A KR101872916B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041768A KR101909235B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041759A KR101872918B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041767A KR101841256B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041770A KR101792029B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041756A KR101841255B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041761A KR101815000B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041757A KR101855094B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041758A KR101872917B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041769A KR101851625B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041760A KR101850711B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041766A KR101809754B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120041765A KR101814999B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047636A KR101909236B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047637A KR20130083795A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047635A KR20130083793A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047640A KR101904916B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120047642A KR101839484B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120047638A KR101904917B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120047639A KR101853902B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
| KR1020120047641A KR101931977B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
| KR1020120048923A KR101931978B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
| KR1020120048924A KR101855095B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
| KR1020120048928A KR101847013B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
| KR1020120048926A KR20130083804A (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
| KR1020120048927A KR101909237B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
| KR1020120048925A KR101847012B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
Country Status (1)
| Country | Link |
|---|---|
| KR (38) | KR101832285B1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101453190B1 (en) * | 2013-01-17 | 2014-10-22 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle containing amarogentin |
| FR3010307B1 (en) * | 2013-09-12 | 2017-05-05 | Basf Beauty Care Solutions France Sas | COSMETIC OR DERMATOLOGICAL USE OF AVICULARIN |
| CN103520092B (en) * | 2013-10-29 | 2015-10-28 | 浙江中医药大学 | Monocrotaline gel and preparation method thereof |
| KR101909740B1 (en) | 2013-10-30 | 2018-10-18 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising Monotropein |
| KR101909739B1 (en) | 2013-10-30 | 2018-10-18 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation and skin whitening comprising Harpagide |
| KR102040157B1 (en) * | 2013-10-30 | 2019-11-04 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising linderalactone |
| KR20150049417A (en) * | 2013-10-30 | 2015-05-08 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation and skin whitening comprising Harpagoside |
| KR102282748B1 (en) | 2013-11-18 | 2021-07-29 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening |
| KR102013128B1 (en) * | 2013-11-20 | 2019-08-22 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Tridecane for Skin Benefit Ingredient |
| US9914289B2 (en) | 2014-01-08 | 2018-03-13 | Lg Chem, Ltd. | System for laminating optical film and method for manufacturing display unit using the same |
| KR102142492B1 (en) * | 2014-08-13 | 2020-08-07 | 주식회사 엘지생활건강 | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising aurantio-obtusin or a pharmaceutically acceptable salt thereof |
| KR102199884B1 (en) * | 2014-10-15 | 2021-01-08 | (주)아모레퍼시픽 | Composition for controlling sebum containing a substance related to regulation of ABH antigen expression |
| KR102224110B1 (en) * | 2014-10-15 | 2021-03-09 | (주)아모레퍼시픽 | Composition for reducing the skin pore containing a substance related to regulation of ABH antigen expression |
| CN104288167B (en) * | 2014-10-29 | 2017-08-25 | 马应龙药业集团股份有限公司 | It is a kind of to treat otoginsenoside preparation of sodium of hemorrhoid and preparation method thereof |
| KR102553374B1 (en) | 2016-06-14 | 2023-07-06 | 주식회사 엘지생활건강 | Composition for prevention or treatment of dental disease comprising cistanoside A |
| CN106176606B (en) * | 2016-08-08 | 2019-01-01 | 武汉爱民制药股份有限公司 | sodium aescinate aerosol |
| CN107759656A (en) * | 2016-08-22 | 2018-03-06 | 黑龙江迪龙制药有限公司 | A kind of preparation method of Sodium Aescinate |
| KR20180058411A (en) * | 2016-11-24 | 2018-06-01 | 대한민국(환경부 국립생물자원관장) | Cosmetic composition for antioxidant comprising Alnus firma extract as active ingredients |
| KR101907850B1 (en) * | 2017-04-07 | 2018-10-15 | 한국 한의학 연구원 | Composition for improving skin wrinkle or skin moisturing comprising Protaetia brevitarsis extract or compound isolated therefrom as effective component |
| KR102053994B1 (en) * | 2017-12-22 | 2019-12-10 | 재단법인 전주농생명소재연구원 | Cosmetic composition for skin whitening and moisturizing comprising larva extract of Protaetia brevitarsis as effective component |
| CN110314122B (en) * | 2018-03-30 | 2023-04-07 | 广州箴美科技有限公司 | Alisma extract and preparation method and application thereof |
| KR102633917B1 (en) * | 2019-05-30 | 2024-02-06 | (주)아모레퍼시픽 | Composition for reinforcing skin elasticity |
| CN111534483B (en) * | 2020-05-23 | 2020-12-18 | 广东壹加再生医学研究院有限公司 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
| CN111529426A (en) * | 2020-06-13 | 2020-08-14 | 南京奥赛斯生物科技有限公司 | Application of plant small molecules in improving skin elasticity and preparing beauty skin care products |
| KR102431445B1 (en) * | 2020-09-21 | 2022-08-11 | 주식회사 서미바이오 | Method for manufacturing cream-type cosmetic product containing grub powder |
| US11925701B2 (en) | 2020-10-27 | 2024-03-12 | Tci Co., Ltd. | Method for skin conditioning by using Dan Feng peony extract |
| KR102611368B1 (en) * | 2020-12-03 | 2023-12-06 | 제주대학교 산학협력단 | A composition for promoting melanin synthesis comprising didymin |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617216A (en) * | 1984-06-21 | 1986-01-13 | Shiseido Co Ltd | External remedy for skin |
| JP3135293B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
| JPH0517336A (en) * | 1991-07-10 | 1993-01-26 | Shiseido Co Ltd | Skin medicine for external use |
| JP3135294B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
| JP3135295B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
| JP3135292B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
| JP2829157B2 (en) * | 1991-07-10 | 1998-11-25 | 株式会社資生堂 | External preparation for skin |
| JP3251635B2 (en) * | 1992-03-19 | 2002-01-28 | 株式会社資生堂 | External preparation for skin |
| JP3443130B2 (en) * | 1992-03-19 | 2003-09-02 | 株式会社資生堂 | External preparation for skin |
| FR2695561B1 (en) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Cosmetic or dermatological composition containing at least one ginsenoside-type saponin, and its applications, in particular for hair care. |
| US5529769A (en) | 1994-12-20 | 1996-06-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing betulinic acid |
| JPH08231370A (en) | 1995-02-23 | 1996-09-10 | Taiyo Kagaku Co Ltd | Skin cosmetic |
| JPH0940523A (en) | 1995-07-28 | 1997-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoter containing water extract form chlorella |
| JPH0967388A (en) * | 1995-08-31 | 1997-03-11 | Shiseido Co Ltd | Production of saikosaponin |
| JPH0977632A (en) * | 1995-09-14 | 1997-03-25 | Shiseido Co Ltd | Dermal preparation for external use |
| JP3966922B2 (en) | 1996-07-18 | 2007-08-29 | 一丸ファルコス株式会社 | Fibroblast growth promoter |
| KR100358937B1 (en) | 1998-04-23 | 2003-03-17 | 주식회사 엘지생명과학 | Water-soluble extract of anemarrhena asphodeloides bunge having growth hormone release stimulating activity and growth hormone release stimulating factor separated therefrom |
| JP2001039850A (en) * | 1999-07-27 | 2001-02-13 | Shiseido Co Ltd | Agent for accelerating shrinkage of collagen gel |
| JP2001352938A (en) * | 2000-06-16 | 2001-12-25 | Rasheru Seiyaku Kk | Health food |
| JP2002187816A (en) | 2000-10-10 | 2002-07-05 | Noevir Co Ltd | Bleaching cosmetic |
| KR20020044855A (en) * | 2000-12-07 | 2002-06-19 | 성재갑 | Oral compositions containing xanthorrhizol as an inhibitor of reactive oxygen species and nitric oxide for dental hygiene |
| US6589514B2 (en) | 2001-04-17 | 2003-07-08 | Morinda, Inc. | Cosmetic intensive repair serum with morinda citrifolia |
| KR101001815B1 (en) | 2001-12-14 | 2010-12-15 | 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 | A composition for treating neurocerebrovascular disorders |
| CN100471490C (en) | 2002-08-01 | 2009-03-25 | 谢恬 | Sesquiterpene ketone injection, preparing method and use thereof |
| US20040161435A1 (en) * | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
| CN1893911B (en) * | 2003-11-17 | 2010-12-29 | 赛德玛公司 | Formula including tetrapeptide and tripeptide mixture |
| KR20050082447A (en) * | 2004-02-19 | 2005-08-24 | 주식회사 엠디바이오알파 | Diabete treatment with tetrahydroberberine |
| KR20050092313A (en) * | 2004-03-15 | 2005-09-21 | 주식회사 엘지생활건강 | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation |
| JP2005281284A (en) * | 2004-03-26 | 2005-10-13 | Ivy Cosmetics Corp | Skin care preparation for external use for promoting collagen synthesis |
| EP1753428A4 (en) | 2004-05-14 | 2010-09-15 | Abbott Lab | Kinase inhibitors as therapeutic agents |
| US20050271608A1 (en) | 2004-06-05 | 2005-12-08 | Gupta Shyam K | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives |
| US20070166255A1 (en) * | 2004-11-22 | 2007-07-19 | Gupta Shyam K | Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition |
| CN1676165A (en) | 2004-12-29 | 2005-10-05 | 山东蓝金生物工程有限公司 | In vivo slow-releasing anticancer medicinal composition |
| CN1872083B (en) | 2005-05-31 | 2010-07-21 | 山东绿叶天然药物研究开发有限公司 | Application of monarda glycoside in preparing medicine for treating or preventing hemorrhagic disease |
| JP4861753B2 (en) | 2006-06-20 | 2012-01-25 | 花王株式会社 | Skin external composition |
| KR101613739B1 (en) * | 2007-09-11 | 2016-04-19 | 디에스엠 아이피 어셋츠 비.브이. | Sesquiterpenes and derivatives thereof for use as feed additives |
| CN101474274B (en) | 2008-12-24 | 2012-06-27 | 贵州信邦制药股份有限公司 | Quality control method of Shensu Chinese medicine preparation |
| DE102009002227A1 (en) | 2009-04-06 | 2010-10-07 | Henkel Ag & Co. Kgaa | Skin treatment against skin aging I |
| KR101100678B1 (en) * | 2009-06-04 | 2012-01-03 | 웅진코웨이주식회사 | Cosmetic Composition comprising plant extracts |
| CN102107006A (en) | 2009-12-25 | 2011-06-29 | 奇复康药物研发(苏州)有限公司 | Coupling medicament for treating diabetes mellitus and medicinal application thereof |
| JP2012001467A (en) * | 2010-06-15 | 2012-01-05 | Naris Cosmetics Co Ltd | Skin external preparation |
-
2012
- 2012-04-17 KR KR1020120039942A patent/KR101832285B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039950A patent/KR20130083778A/en not_active Application Discontinuation
- 2012-04-17 KR KR1020120039943A patent/KR101890322B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039945A patent/KR101792031B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039944A patent/KR20130083772A/en not_active Application Discontinuation
- 2012-04-17 KR KR1020120039946A patent/KR101832286B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039941A patent/KR101832284B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039949A patent/KR101637375B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039948A patent/KR101809753B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039947A patent/KR101792028B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039940A patent/KR101832283B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039951A patent/KR101872916B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041768A patent/KR101909235B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041759A patent/KR101872918B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041767A patent/KR101841256B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041770A patent/KR101792029B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041756A patent/KR101841255B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041761A patent/KR101815000B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041757A patent/KR101855094B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041758A patent/KR101872917B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041769A patent/KR101851625B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041760A patent/KR101850711B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041766A patent/KR101809754B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041765A patent/KR101814999B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047636A patent/KR101909236B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047637A patent/KR20130083795A/en not_active Application Discontinuation
- 2012-05-04 KR KR1020120047635A patent/KR20130083793A/en not_active Application Discontinuation
- 2012-05-04 KR KR1020120047640A patent/KR101904916B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047642A patent/KR101839484B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047638A patent/KR101904917B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047639A patent/KR101853902B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047641A patent/KR101931977B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048923A patent/KR101931978B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048924A patent/KR101855095B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048928A patent/KR101847013B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048926A patent/KR20130083804A/en not_active Application Discontinuation
- 2012-05-09 KR KR1020120048927A patent/KR101909237B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048925A patent/KR101847012B1/en active IP Right Grant
Non-Patent Citations (1)
| Title |
|---|
| Shijie Huaren Xiaohua Zazhi, 15(1), pp. 22-28 (20070108) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101832286B1 (en) | Composition for improving skin wrinkle and enhancing elasticity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |